Bipartisan Policy Center Comments on FDA's Generative AI-Enabled Medical Devices Framework
OVERVIEWThe Bipartisan Policy Center submitted detailed comments to the FDA on the agency's proposed framework for regulating generative AI-enabled medical devices. BPC's analysis emphasizes the need for balanced regulation that accelerates beneficial AI innovations while maintaining safety oversight. Key recommendations include: establishing risk-based regulatory pathways proportional to clinical risk; requiring real-world performance monitoring for adaptive AI systems; clarifying liability frameworks for AI-assisted clinical decisions; and developing standards for AI training data quality and transparency. BPC advocates for the FDA's TEMPO Pilot approach, which allows certain generative AI devices to reach patients under post-market surveillance rather than waiting for complete pre-market evidence. The center's input reflects bipartisan consensus that AI regulation should enable innovation while protecting patient safety—a middle ground between industry calls for minimal oversight and consumer advocates' demands for stringent pre-market testing. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.